Loading…
79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs
Saved in:
| Published in: | ESMO open 2023-05, Vol.8 (1), p.101302, Article 101302 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | 1 |
| container_start_page | 101302 |
| container_title | ESMO open |
| container_volume | 8 |
| creator | Dimitrakopoulos, F-I.D. Goussia, A. Koliou, G.A. Dadouli, K. Batistatou, A. Kourea, H.P. Bobos, M. Arapantoni-Dadioti, P. Tzaida, O. Koletsa, T. Chrisafi, S. Sotiropoulou, M. Papoudou-Bai, A. Nicolaou, I. Charchanti, A. Pectasides, D.G. Koutras, A. Zagouri, F. Gogas, H. Fountzilas, G. |
| description | |
| doi_str_mv | 10.1016/j.esmoop.2023.101302 |
| format | article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1016_j_esmoop_2023_101302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2059702923005288</els_id><sourcerecordid>S2059702923005288</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1462-a4cb6772b567623c4f88863bc95313ca8f40651b27d451f110ae2580279ed9d23</originalsourceid><addsrcrecordid>eNp9kc1v1DAQxQMCiar0wJ2DT5zIYjvfHJCqCmilleCwnCNnPOl6ldjB42yb_x6HQMWJk0fPer959kuSt4LvBBflh9MOaXRu2kkus1XKuHyeXEheNGnFZfPin_lVckV04pyLKo9iefHsTdV8Zwe06YLKMxiMNaAG5uYAbsT3LLhHAyYsTFnNojQNRllA5nqmHWGq0RIywp8z2mCiU-nTfFY2xGGMMApeBePsaoAFBjcdHU1HNRqN7B3Dyfi5ixss690wuAfUrFsiGjCoRxxYvJgiIMKJPZhwZDHmsLDOo6LAYM3iP7LryO8I_fn3rpiCwqyXzQDOwux9JETYGSmY-6dEZO6t6Q38fdLhbk-vk5e9Ggiv_pyXyY8vnw83t-n-29e7m-t9CiIvZapy6Mqqkl1RVqXMIO_rui6zDpoiExmous95WYhOVjovRC8EVyiLmsuqQd1omV0m-cYF74g89u3kzaj80grers22p3Zrtl2bbbdmo-3TZsOY7WzQtwTxewC18Qih1c78H_ALtTW1Ng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs</title><source>ScienceDirect</source><source>PubMed Central</source><creator>Dimitrakopoulos, F-I.D. ; Goussia, A. ; Koliou, G.A. ; Dadouli, K. ; Batistatou, A. ; Kourea, H.P. ; Bobos, M. ; Arapantoni-Dadioti, P. ; Tzaida, O. ; Koletsa, T. ; Chrisafi, S. ; Sotiropoulou, M. ; Papoudou-Bai, A. ; Nicolaou, I. ; Charchanti, A. ; Pectasides, D.G. ; Koutras, A. ; Zagouri, F. ; Gogas, H. ; Fountzilas, G.</creator><creatorcontrib>Dimitrakopoulos, F-I.D. ; Goussia, A. ; Koliou, G.A. ; Dadouli, K. ; Batistatou, A. ; Kourea, H.P. ; Bobos, M. ; Arapantoni-Dadioti, P. ; Tzaida, O. ; Koletsa, T. ; Chrisafi, S. ; Sotiropoulou, M. ; Papoudou-Bai, A. ; Nicolaou, I. ; Charchanti, A. ; Pectasides, D.G. ; Koutras, A. ; Zagouri, F. ; Gogas, H. ; Fountzilas, G.</creatorcontrib><identifier>ISSN: 2059-7029</identifier><identifier>EISSN: 2059-7029</identifier><identifier>DOI: 10.1016/j.esmoop.2023.101302</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>ESMO open, 2023-05, Vol.8 (1), p.101302, Article 101302</ispartof><rights>2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2059702923005288$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids></links><search><creatorcontrib>Dimitrakopoulos, F-I.D.</creatorcontrib><creatorcontrib>Goussia, A.</creatorcontrib><creatorcontrib>Koliou, G.A.</creatorcontrib><creatorcontrib>Dadouli, K.</creatorcontrib><creatorcontrib>Batistatou, A.</creatorcontrib><creatorcontrib>Kourea, H.P.</creatorcontrib><creatorcontrib>Bobos, M.</creatorcontrib><creatorcontrib>Arapantoni-Dadioti, P.</creatorcontrib><creatorcontrib>Tzaida, O.</creatorcontrib><creatorcontrib>Koletsa, T.</creatorcontrib><creatorcontrib>Chrisafi, S.</creatorcontrib><creatorcontrib>Sotiropoulou, M.</creatorcontrib><creatorcontrib>Papoudou-Bai, A.</creatorcontrib><creatorcontrib>Nicolaou, I.</creatorcontrib><creatorcontrib>Charchanti, A.</creatorcontrib><creatorcontrib>Pectasides, D.G.</creatorcontrib><creatorcontrib>Koutras, A.</creatorcontrib><creatorcontrib>Zagouri, F.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><creatorcontrib>Fountzilas, G.</creatorcontrib><title>79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs</title><title>ESMO open</title><issn>2059-7029</issn><issn>2059-7029</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kc1v1DAQxQMCiar0wJ2DT5zIYjvfHJCqCmilleCwnCNnPOl6ldjB42yb_x6HQMWJk0fPer959kuSt4LvBBflh9MOaXRu2kkus1XKuHyeXEheNGnFZfPin_lVckV04pyLKo9iefHsTdV8Zwe06YLKMxiMNaAG5uYAbsT3LLhHAyYsTFnNojQNRllA5nqmHWGq0RIywp8z2mCiU-nTfFY2xGGMMApeBePsaoAFBjcdHU1HNRqN7B3Dyfi5ixss690wuAfUrFsiGjCoRxxYvJgiIMKJPZhwZDHmsLDOo6LAYM3iP7LryO8I_fn3rpiCwqyXzQDOwux9JETYGSmY-6dEZO6t6Q38fdLhbk-vk5e9Ggiv_pyXyY8vnw83t-n-29e7m-t9CiIvZapy6Mqqkl1RVqXMIO_rui6zDpoiExmous95WYhOVjovRC8EVyiLmsuqQd1omV0m-cYF74g89u3kzaj80grers22p3Zrtl2bbbdmo-3TZsOY7WzQtwTxewC18Qih1c78H_ALtTW1Ng</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Dimitrakopoulos, F-I.D.</creator><creator>Goussia, A.</creator><creator>Koliou, G.A.</creator><creator>Dadouli, K.</creator><creator>Batistatou, A.</creator><creator>Kourea, H.P.</creator><creator>Bobos, M.</creator><creator>Arapantoni-Dadioti, P.</creator><creator>Tzaida, O.</creator><creator>Koletsa, T.</creator><creator>Chrisafi, S.</creator><creator>Sotiropoulou, M.</creator><creator>Papoudou-Bai, A.</creator><creator>Nicolaou, I.</creator><creator>Charchanti, A.</creator><creator>Pectasides, D.G.</creator><creator>Koutras, A.</creator><creator>Zagouri, F.</creator><creator>Gogas, H.</creator><creator>Fountzilas, G.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202305</creationdate><title>79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs</title><author>Dimitrakopoulos, F-I.D. ; Goussia, A. ; Koliou, G.A. ; Dadouli, K. ; Batistatou, A. ; Kourea, H.P. ; Bobos, M. ; Arapantoni-Dadioti, P. ; Tzaida, O. ; Koletsa, T. ; Chrisafi, S. ; Sotiropoulou, M. ; Papoudou-Bai, A. ; Nicolaou, I. ; Charchanti, A. ; Pectasides, D.G. ; Koutras, A. ; Zagouri, F. ; Gogas, H. ; Fountzilas, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1462-a4cb6772b567623c4f88863bc95313ca8f40651b27d451f110ae2580279ed9d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dimitrakopoulos, F-I.D.</creatorcontrib><creatorcontrib>Goussia, A.</creatorcontrib><creatorcontrib>Koliou, G.A.</creatorcontrib><creatorcontrib>Dadouli, K.</creatorcontrib><creatorcontrib>Batistatou, A.</creatorcontrib><creatorcontrib>Kourea, H.P.</creatorcontrib><creatorcontrib>Bobos, M.</creatorcontrib><creatorcontrib>Arapantoni-Dadioti, P.</creatorcontrib><creatorcontrib>Tzaida, O.</creatorcontrib><creatorcontrib>Koletsa, T.</creatorcontrib><creatorcontrib>Chrisafi, S.</creatorcontrib><creatorcontrib>Sotiropoulou, M.</creatorcontrib><creatorcontrib>Papoudou-Bai, A.</creatorcontrib><creatorcontrib>Nicolaou, I.</creatorcontrib><creatorcontrib>Charchanti, A.</creatorcontrib><creatorcontrib>Pectasides, D.G.</creatorcontrib><creatorcontrib>Koutras, A.</creatorcontrib><creatorcontrib>Zagouri, F.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><creatorcontrib>Fountzilas, G.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>ESMO open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dimitrakopoulos, F-I.D.</au><au>Goussia, A.</au><au>Koliou, G.A.</au><au>Dadouli, K.</au><au>Batistatou, A.</au><au>Kourea, H.P.</au><au>Bobos, M.</au><au>Arapantoni-Dadioti, P.</au><au>Tzaida, O.</au><au>Koletsa, T.</au><au>Chrisafi, S.</au><au>Sotiropoulou, M.</au><au>Papoudou-Bai, A.</au><au>Nicolaou, I.</au><au>Charchanti, A.</au><au>Pectasides, D.G.</au><au>Koutras, A.</au><au>Zagouri, F.</au><au>Gogas, H.</au><au>Fountzilas, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs</atitle><jtitle>ESMO open</jtitle><date>2023-05</date><risdate>2023</risdate><volume>8</volume><issue>1</issue><spage>101302</spage><pages>101302-</pages><artnum>101302</artnum><issn>2059-7029</issn><eissn>2059-7029</eissn><pub>Elsevier Ltd</pub><doi>10.1016/j.esmoop.2023.101302</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2059-7029 |
| ispartof | ESMO open, 2023-05, Vol.8 (1), p.101302, Article 101302 |
| issn | 2059-7029 2059-7029 |
| language | eng |
| recordid | cdi_crossref_primary_10_1016_j_esmoop_2023_101302 |
| source | ScienceDirect; PubMed Central |
| title | 79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A10%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=79P%20Ten-year%20clinical%20outcome,%20toxicity%20and%20compliance%20of%20dose-dense%20sequential%20adjuvant%20administration%20of%20cyclophosphamide%20&%20epirubicin%20followed%20by%20docetaxel%20in%20patients%20with%20early%20breast%20cancer:%20An%20observational%20study%20with%20concurrent%20investigation%20of%20significance%20of%20TILs&rft.jtitle=ESMO%20open&rft.au=Dimitrakopoulos,%20F-I.D.&rft.date=2023-05&rft.volume=8&rft.issue=1&rft.spage=101302&rft.pages=101302-&rft.artnum=101302&rft.issn=2059-7029&rft.eissn=2059-7029&rft_id=info:doi/10.1016/j.esmoop.2023.101302&rft_dat=%3Celsevier_cross%3ES2059702923005288%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1462-a4cb6772b567623c4f88863bc95313ca8f40651b27d451f110ae2580279ed9d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |